Unraveling the molecular biology of normal karyotype AML
EHA Library. Vassiliou G. 06/14/15; 103568 Topic: 2B Acute myeloid leukemia (AML) and leukemias of ambiguous lineage
Disclosure(s): Kymab (consultant & stockholder) Celgene (research grant)
Wellcome Trust Sanger Institute
Dr. George Vassiliou
Dr. George Vassiliou
Contributions
Learning Objectives
After viewing this presentation the participant will be able to:
− Recognize the spectrum and molecular groups of mutations driving AML-NK and related myeloid neoplasms.
− Appreciate the pre-clinical clonal evolution and subclonal structure of AML-NK.
− Understand the known molecular effects of the most common mutations and how these promote leukemogenesis alone and in collaboration.
− Identify the prognostic impact and therapeutic implications of particular mutations.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies